School of Medicine, South China University of Technology, Guangzhou, China.
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
J Hepatol. 2024 Oct;81(4):690-703. doi: 10.1016/j.jhep.2024.05.007. Epub 2024 May 15.
BACKGROUND & AIMS: The liver is the main organ of ketogenesis, while ketones are mainly metabolized in peripheral tissues via the critical enzyme 3-oxoacid CoA-transferase 1 (OXCT1). We previously found that ketolysis is reactivated in hepatocellular carcinoma (HCC) cells through OXCT1 expression to promote tumor progression; however, whether OXCT1 regulates antitumor immunity remains unclear.
To investigate the expression pattern of OXCT1 in HCC in vivo, we conducted multiplex immunohistochemistry experiments on human HCC specimens. To explore the role of OXCT1 in mouse HCC tumor-associated macrophages (TAMs), we generated LysMOXCT1 (OXCT1 conditional knockout in macrophages) mice.
Here, we found that inhibiting OXCT1 expression in tumor-associated macrophages reduced CD8 T-cell exhaustion through the succinate-H3K4me3-Arg1 axis. Initially, we found that OXCT1 was highly expressed in liver macrophages under steady state and that OXCT expression was further increased in TAMs. OXCT1 deficiency in macrophages suppressed tumor growth by reprogramming TAMs toward an antitumor phenotype, reducing CD8 T-cell exhaustion and increasing CD8 T-cell cytotoxicity. Mechanistically, high OXCT1 expression induced the accumulation of succinate, a byproduct of ketolysis, in TAMs, which promoted Arg1 transcription by increasing the H3K4me3 level in the Arg1 promoter. In addition, pimozide, an inhibitor of OXCT1, suppressed Arg1 expression as well as TAM polarization toward the protumor phenotype, leading to decreased CD8 T-cell exhaustion and slower tumor growth. Finally, high expression of OXCT1 in macrophages was positively associated with poor survival in patients with HCC.
In conclusion, our results demonstrate that OXCT1 epigenetically suppresses antitumor immunity, suggesting that suppressing OXCT1 activity in TAMs could be an effective approach for treating liver cancer.
The intricate metabolism of liver macrophages plays a critical role in shaping hepatocellular carcinoma progression and immune modulation. Targeting macrophage metabolism to counteract immune suppression presents a promising avenue for hepatocellular carcinoma treatment. Herein, we found that the ketogenesis gene OXCT1 was highly expressed in tumor-associated macrophages (TAMs) and promoted tumor growth by reprogramming TAMs toward a protumor phenotype. Pharmacological targeting or genetic downregulation of OXCT1 in TAMs enhances antitumor immunity and slows tumor growth. Our results suggest that suppressing OXCT1 activity in TAMs could be an effective approach for treating liver cancer.
肝脏是酮体生成的主要器官,而酮体主要在周围组织中通过关键酶 3-氧代酸 CoA 转移酶 1(OXCT1)进行代谢。我们之前发现,通过 OXCT1 表达,肝癌(HCC)细胞中的酮解重新激活,以促进肿瘤进展;然而,OXCT1 是否调节抗肿瘤免疫尚不清楚。
为了研究 OXCT1 在体内 HCC 中的表达模式,我们对人 HCC 标本进行了多重免疫组化实验。为了探讨 OXCT1 在小鼠 HCC 肿瘤相关巨噬细胞(TAMs)中的作用,我们生成了 LysMOXCT1(巨噬细胞中 OXCT1 的条件性敲除)小鼠。
在这里,我们发现抑制肿瘤相关巨噬细胞中的 OXCT1 表达通过琥珀酸-H3K4me3-Arg1 轴减少 CD8 T 细胞衰竭。最初,我们发现 OXCT1 在静息状态下在肝巨噬细胞中高表达,并且在 TAMs 中进一步增加。巨噬细胞中 OXCT1 的缺失通过重编程 TAMs 向抗肿瘤表型抑制肿瘤生长,减少 CD8 T 细胞衰竭并增加 CD8 T 细胞细胞毒性。机制上,高 OXCT1 表达诱导酮解的副产物琥珀酸在 TAMs 中的积累,通过增加 Arg1 启动子中的 H3K4me3 水平促进 Arg1 转录。此外,OXCT1 的抑制剂匹莫齐特抑制 Arg1 表达以及 TAM 向促肿瘤表型的极化,导致 CD8 T 细胞衰竭减少和肿瘤生长减慢。最后,巨噬细胞中 OXCT1 的高表达与 HCC 患者的不良生存呈正相关。
总之,我们的结果表明,OXCT1 通过表观遗传抑制抗肿瘤免疫,提示抑制 TAMs 中的 OXCT1 活性可能是治疗肝癌的有效方法。
肝巨噬细胞的复杂代谢在塑造肝细胞癌进展和免疫调节中起着关键作用。针对巨噬细胞代谢来对抗免疫抑制为肝细胞癌的治疗提供了一个很有前途的途径。在这里,我们发现酮体生成基因 OXCT1 在肿瘤相关巨噬细胞(TAMs)中高表达,并通过重编程 TAMs 向促肿瘤表型促进肿瘤生长。在 TAMs 中,药物靶向或 OXCT1 的遗传下调增强了抗肿瘤免疫并减缓了肿瘤生长。我们的结果表明,抑制 TAMs 中的 OXCT1 活性可能是治疗肝癌的有效方法。